BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//IAS-USA//NONSGML PDA Calendar Version 1.0//EN
CALSCALE:GREGORIAN
BEGIN:VEVENT
UID:7c63abaa5d945f501bfa3d5539b42e06
ORGANIZER:registration@iasusa.org
DTSTAMP:20261027T182218Z
LOCATION:
SUMMARY:Next-Generation Regimens for Hepatitis C Virus Infection and Their Role in the Clinic
DESCRIPTION:Overview\n\nAssessment of Needs\nThe IAS–USA offers this state-of-the-art activity on the evolving challenges of managing HCV disease as part of a nationwide continuing medical education (CME) effort for physicians. The current armamentarium of direct-acting antiviral (DAA) treatments for hepatitis C virus (HCV) infection is vast. Among currently available treatments are 1-pill coformulations\; US Food and Drug Administration (FDA)–approved pangenotypic regimens\; and regimens to treat HCV infection in persons with severe comorbidities such as chronic kidney disease\, end-stage renal disease\, and decompensated cirrhosis. In light of the possible availability of 2 new coformulations\, including the first triple drug regimen for HCV-infected treatment-experienced persons\, this webinar will review available data for these currently investigational regimens.\nLearning Objectives\nAt the conclusion of this webinar\, participants will be able to:\n\n 	Name 2 investigational HCV regimens pending approval by the FDA\n 	Describe the safety and efficacy of these investigational DAA regimens\n 	Describe which HCV-infected individuals might benefit from these regimens\, if available\n\nRegistration\nWho Should Attend\nThis webinar is designed for physicians who have a good understanding of the basics of HCV transmission\, testing\, and management\, and have managed HCV infection in at least 5 patients.\n\nThis activity is also relevant to nurse practitioners\, registered nurses\, physician assistants\, registered pharmacists\, and other health professionals.\n\nIndividual registration is required\, even if you are viewing as a group\, in order to receive CME credit or a certificate of participation.\n\nRegistration closes on Wednesday\, June 28\, 2017\, 4:00 PM (PT).\n\nCertificates will be available after the completion of the evaluation and claim form.\n\nFor more information or questions\, please contact the registration department at registration@iasusa.org or 415-544-9400.\nConflicts of Interest\nIn the interest of maintaining the independence of its CME activities\, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME)\, the IAS–USA requires all persons with control of content (eg\, faculty\, IAS–USA Board members\, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.\n\n\n\n\nContinuing Education Credits\n\nCME Credits\nThe International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.\n\nThe IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.\nNursing Credits\nEducational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association\, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.  Provider # 5-115.  This program is approved for 1.5 hours of continuing nursing education.\n\nEducational Review Systems is also approved for nursing continuing education by the state of California\, the state of Florida and the District of Columbia.\nPharmacy Credits\nEducational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.5 hours (0.15 CEUs) of continuing pharmacy education credit.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.\nUAN  # 0761-9999-17-094-L01-P\n\n\n\n\nGrant Support\n\n\nThis activity is part of the IAS–USA national educational effort that is funded\, in part\, by charitable contributions from commercial companies. Per IAS–USA policy\, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity\, including its content\, development\, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.\n\nGOLD SUPPORTERS\nGilead Sciences\, Inc\nMerck\n\nBRONZE SUPPORTER\nAbbVie\nFrequently Asked Questions\nView our list of FAQs about attending a webinar.\n\nFurther Questions?\nPlease contact the registration department at registration@iasusa.org or 415-544-9400.
STATUS:CONFIRMED
CATEGORIES:Webinars
URL;VALUE=URI:https://www.iasusa.org/events/webinar-2017-naggie/
DTSTART:20170629T170000Z
DTEND:20170629T183000Z
END:VEVENT
END:VCALENDAR